GC has been granted a patent for a novel antibody library featuring a human sequence-derived scaffold. This library allows for high thermodynamic stability and soluble expression, enabling the development of antibodies with high specificity and affinity for various antigens, enhancing candidate selection against target antigens. GlobalData’s report on GC gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights GC Corp - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on GC, Personalized cancer vaccines was a key innovation area identified from patents. GC's grant share as of July 2024 was 46%. Grant share is based on the ratio of number of grants to total number of patents.

Novel antibody library and screening method

Source: United States Patent and Trademark Office (USPTO). Credit: GC Corp

The patent US12071710B2 describes a novel set of antibodies or their fragments characterized by specific heavy-chain and light-chain variable regions. Each antibody or fragment includes a heavy-chain variable region that features a framework region selected from VH3-15, VH3-23, or VH1-69, along with unique combinations of complementarity-determining regions (CDRs). The light-chain variable region is similarly defined by framework regions from VK1-39, V?3-20, V?3-20-2, or V?1-51, each also possessing distinct CDR combinations. The claims detail the specific sequences and structural components that contribute to the antibodies' functionality, emphasizing the diversity and specificity of the CDRs.

Additionally, the patent outlines methods for identifying antibodies that bind to specific antigens using the described set. The antibodies or fragments can be expressed on the surface of phages or host cells, such as E. coli or yeast, which facilitates the selection process. The claims also highlight various characteristics of the antibodies, including low redundancy, high thermal stability, and significant library diversity. This innovative approach to antibody design and identification may enhance the development of targeted therapies and diagnostics in various biomedical applications.

To know more about GlobalData’s detailed insights on GC, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies